Hematology Home >
- Faculty
David J. Vaughn, M.D.Professor of Medicine at the Hospital of the University of Pennsylvania
Attending Physician
Physician Practice Leader (Solid Tumor Oncology)
Adjunct Faculty Member
Director
Department: Medicine
Contact information
Abramson Cancer Center of the University of Pennsylvania
16 Penn Tower 3400 Spruce Street Philadelphia, PA 19104
Office: 215-349-8140
Fax: 215-662-7804 Email: david.vaughn@uphs.upenn.edu
Education:
A.B. (Spanish) Dartmouth College, 1982. M.D. (Medicine) Harvard Medical School, 1987.
Post-Graduate Training
Internship, The New York Hospital-Cornell Medical Center (Medicine), 1987-1988. Residency, The New York Hospital-Cornell Medical Center (Medicine), 1988-1990. Fellowship, Hospital of the University of Pennsylvania (Hematology/Oncology), 1990-1993.
Certifications
Permanent linkAmerican Board of Internal Medicine, 1990. Subspecialty, Medical Oncology, 1993. Recertification, Medical Oncology, 2003. Description of Research ExpertiseNew Drug Development for Urologic CancerCancer Survivorship Description of Clinical ExpertiseUrologic OncologyBladder Cancer Prostate Cancer Testis Cancer Cancer Survivorship Selected PublicationsWhittington R, Vaughn DJ: Prostate cancer. Oncology: An Evidence-Based Approach. Chang AE, Ganz PA, Hayes DF, Kinsella TJ, Pass HI, Schiller JH, Stone RM, Strecher VJ. (eds.). Springer, New York, Page: 826-43, 2006.Latif T, Wood L, Connell C, Smith DC, Vaughn D, Lebwohl D, Peereboom D: Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platunum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer. Investigational New Drugs 23(1): 79-84, January 2005. Zoltick BH, Jacobs LA, Vaughn DJ: Cardiovascular risk in testicular cancer survivors treated with chemotherapy: incidence, significance, and practice implications. Oncology Nursing Forum 32(5): 1005-9, Sep 2005. Bilenker JH, Flaherty KT, Rosen M, Davis L, Gallagher M, Stevenson J, Sun W, Vaughn D, Giantonio B, Zimmer R, O'Dwyer PJ: Phase I trial of combretastatin a-4 phosphate with carboplatin. Clinical Cancer Research 11(4): 1527-33, February 2005. Vaughn DJ, Rizzo T, Malkowicz SB: Chemosensitivity of malignant ovarian-type surface epithelial tumor of the testis. Urology 66(3): 658, Sep 2005. Vaughn DJ, Malkowicz SB: Neoadjuvant chemotherapy in patients with invasive bladder cancer. Urologic Clinics of North America 32(2): 231-7, May 2005. Vaughn DJ: Editorial comment on "Late relapse of testicular germ cell tumors". Urologic Oncology 23(6): 445-6, November-December 2005. Vaughn DJ, Lubiniecki G, Malkowicz SB: Neoadjuvant chemotherapy in bladder cancer. American Journal of Cancer 4(2): 71-5, July 2005. Rosenberg JE, von der Masse H, Seigne JD, Mardiak J, Vaughn DJ, Moore M, Sahasrabudhe D, Palmer PA, Perez-Ruixo JJ, Small EJ: A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma. Cancer 103(10): 2035-41, May 2005. Campbell C, Soulen MC, Horii SC, Seigelman ES, Rubesin SE, Vaughn DJ: Transrectal radiofrequency ablation for pelvic recurrence of bladder cancer: case report and review of complications. Journal of Vascular Interventional Radiology 16(7): 1027-32, July 2005.
|
